Equities analysts expect VIVUS, Inc. (NASDAQ:VVUS) to report ($0.11) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for VIVUS’s earnings. VIVUS reported earnings of ($0.06) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 83.3%. The firm is expected to issue its next earnings results on Tuesday, November 6th.
On average, analysts expect that VIVUS will report full-year earnings of ($0.44) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.57) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow VIVUS.
VIVUS (NASDAQ:VVUS) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). The firm had revenue of $14.96 million during the quarter. VIVUS had a negative return on equity of 843.43% and a negative net margin of 72.78%.
Several equities research analysts recently issued reports on VVUS shares. Zacks Investment Research raised shares of VIVUS from a “hold” rating to a “buy” rating and set a $0.50 target price for the company in a report on Wednesday, May 16th. ValuEngine raised shares of VIVUS from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.
A hedge fund recently raised its stake in VIVUS stock. Renaissance Technologies LLC raised its stake in shares of VIVUS, Inc. (NASDAQ:VVUS) by 5.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,273,800 shares of the biopharmaceutical company’s stock after buying an additional 423,100 shares during the quarter. Renaissance Technologies LLC owned about 7.79% of VIVUS worth $5,833,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 17.86% of the stock is currently owned by institutional investors and hedge funds.
VIVUS stock opened at $0.55 on Friday. VIVUS has a 12-month low of $0.33 and a 12-month high of $1.02. The company has a current ratio of 4.93, a quick ratio of 4.26 and a debt-to-equity ratio of -10.60.
VIVUS, Inc, a biopharmaceutical company, develops and commercializes novel therapeutic products to address unmet medical needs in human health in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or obese patients, or 27 or greater, or overweight patients in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.
Read More: Fundamental Analysis and Choosing Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.